Introduction
The nucleotides cyclic 3',5'adenosine monophosphate (cAMP) and cyclic 3',5'guanosine monophosphate (cGMP) are important second messengers. Indeed, increased intracellular levels of cAMP or cGMP in both respiratory smooth muscle and inflammatory cells result in bronchodilatation, reduction of inflammation 12 and immunomodulatory activities. ' The intracellular concentration of cyclic nucleotides is mainly determined by intracellular breakdown of cyclic nucleotide by phosphodiesterases (PDEs). PDEs are a family of enzymes which hydrolyse the 3'-ribose phosphate bond of the naturally occurring second messenger nucleotide 3',5'-cyclic monophosphate to form the biologically inert 5'-nucleotide monophosphate.
PDEs are at present divided into at least seven families each with distinct substrate specificities and regulatory characteristics. 3 23 Moreover, an important role for PKG in mediating the relaxant response to cAMP have been noted in rat aortic smooth muscle cells in culture. 24 Recently, Eckly and colleagues 25 reported that PKG is involved in rolipram-induced vascular relaxation of rat aorta. Since rolipram only increased cAMP content, these data also suggest a cross-activation of PKG by cAMP in rat aorta.
In conclusion, we showed that db-cAMP inhibits TNF-c release from human mononuclear cells through a PKA-dependent mechanism. Furthermore, the selective PKG inhibitor, Rp-8-pCPT-cGMPs but not the selective PKA inhibitor, H89 significantly reduced the inhibitory activity of PDE 4 inhibitors on LPS-induced TNF-c release from human mononuclear cells. Therefore, these results suggest a PKA-independent and a PKG-dependent mechanism for the in vitro anti-inflammatory activity of PDE 4 inhibitors, which may be further clarified.
